UA103015C2 - Novel insulin derivatives having an extremely delayed time-action profile - Google Patents

Novel insulin derivatives having an extremely delayed time-action profile

Info

Publication number
UA103015C2
UA103015C2 UAA201009821A UAA201009821A UA103015C2 UA 103015 C2 UA103015 C2 UA 103015C2 UA A201009821 A UAA201009821 A UA A201009821A UA A201009821 A UAA201009821 A UA A201009821A UA 103015 C2 UA103015 C2 UA 103015C2
Authority
UA
Ukraine
Prior art keywords
amino acid
action profile
radical
novel insulin
delayed time
Prior art date
Application number
UAA201009821A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Пауль ХАБЕРМАНН
Герхард ЗАЙПКЕ
Роланд КУРРЛЕ
Гюнтер Мюллер
Марк ЗОММЕРФЕЛЬД
Норберт Теннагельс
Георг ЧАНК
Ульрих ВЕРНЕР
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Priority claimed from PCT/EP2009/000017 external-priority patent/WO2009087081A2/en
Publication of UA103015C2 publication Critical patent/UA103015C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.
UAA201009821A 2008-01-09 2009-01-06 Novel insulin derivatives having an extremely delayed time-action profile UA103015C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (en) 2008-01-09 2008-01-09 New insulin analogs useful for treating diabetes
PCT/EP2009/000017 WO2009087081A2 (en) 2008-01-09 2009-01-06 Novel insulin derivatives having an extremely delayed time-action profile

Publications (1)

Publication Number Publication Date
UA103015C2 true UA103015C2 (en) 2013-09-10

Family

ID=40758369

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201009821A UA103015C2 (en) 2008-01-09 2009-01-06 Novel insulin derivatives having an extremely delayed time-action profile

Country Status (3)

Country Link
CR (1) CR11511A (en)
DE (1) DE102008003568A1 (en)
UA (1) UA103015C2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
ES2772731T3 (en) 2008-10-17 2020-07-08 Sanofi Aventis Deutschland Combination of an insulin and a GLP-1 agonist
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
US8680049B2 (en) 2008-12-15 2014-03-25 Zealand Pharma A/S Glucagon analogues
EP2799447B1 (en) 2008-12-15 2016-11-23 Zealand Pharma A/S Glucagon analogues
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
NZ597981A (en) 2009-07-13 2014-02-28 Zealand Pharma As Acylated glucagon analogues
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
PE20121316A1 (en) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST AND METHIONINE
EP2554183B1 (en) 2009-11-13 2018-04-04 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising a GLP-1-agonist, an insulin, and methionine
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As GLUCAGON ANALOGS
AP2013006671A0 (en) 2010-06-24 2013-01-31 Zealand Pharma As Glucagon analogues
RU2546520C2 (en) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Application of ave0010 for production of medication for treatment of type 2 diabetes mellitus
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (en) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Combination medicine used for blood glucose control in patients with type 2 diabetes
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX356641B (en) 2012-05-03 2018-06-07 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PL2854841T3 (en) 2012-06-04 2017-08-31 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
ES2620111T3 (en) 2012-07-23 2017-06-27 Zealand Pharma A/S Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
KR102394515B1 (en) 2013-10-17 2022-05-09 질랜드 파마 에이/에스 Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX2016005556A (en) 2013-11-06 2016-07-15 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EA201691374A1 (en) 2014-01-20 2016-12-30 Ханми Фарм. Ко., Лтд. INSULIN LONG ACTION AND ITS APPLICATION
AR100639A1 (en) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
AR100695A1 (en) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES THAT INCLUDES INSULIN AND A DUAL AGONIST GLP-1 / GLUCAGÓN
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
ES2949095T3 (en) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
UY36870A (en) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd NEW INSULIN ANALOGS
TWI774694B (en) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 Insulin analogs with reduced affinity to insulin receptor and use thereof
KR20190122706A (en) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 Dosage form of tissue kallikrein 1
TWI798209B (en) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 A conjugate of insulin analog with reduced affinity to insulin receptor and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
IL95495A (en) 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
DE4405388A1 (en) 1994-02-19 1995-08-24 Hoechst Ag Process for the preparation of polyalkyl-1-oxa-diazaspirodecane compounds
DE69737479D1 (en) 1996-08-30 2007-04-26 Novo Nordisk As GLP-1 DERIVATIVES
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (en) 1999-10-02 2001-04-05 Aventis Pharma Gmbh New synthetic derivatives of the C-peptide of proinsulin, useful in the preparation of human insulin or insulin analogs in high yield
DE10108212A1 (en) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusion protein for the secretion of valuable protein in bacterial supernatants
EP1525219B1 (en) 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE102004058306A1 (en) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Process for the preparation of carboxy-terminally amidated peptides
KR101304958B1 (en) 2005-09-14 2013-09-17 에프. 호프만-라 로슈 아게 Cleavage of precursors of insulins by a variant of trypsin

Also Published As

Publication number Publication date
CR11511A (en) 2010-09-13
DE102008003568A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (en) Novel insulin derivatives having an extremely delayed time-action profile
WO2009087082A3 (en) Novel insulin derivatives having an extremely delayed time-action profile
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
NZ743910A (en) Purification of iduronate-2-sulfatase
PE20120358A1 (en) FGF21 MUTANTS AND USES OF THEM
MX2015011243A (en) Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role.
MX337038B (en) Glucagon/glp-1 receptor co-agonists.
MX2020004912A (en) Prostacyclin compounds, compositions and methods of use thereof.
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
CA2651990C (en) Improved antimicrobial peptides
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
MX2010004571A (en) Wo 2009100260 a2 20090813.
WO2010085700A3 (en) Treatment for obesity
NZ595242A (en) Improved anti-serum albumin binding variants
MX353301B (en) Tripeptide compositions and methods for treatment of diabetes.
BR112014013367A2 (en) polypeptide
IN2014DN09367A (en)
WO2013151467A3 (en) Method for producing a recombinant peptide and resultant peptide
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
BR112017019241A2 (en) peptide analog, composition, method for inducing an immune response against an infection, kit, compound and use of a peptide analog
EA201590431A1 (en) WHEAT WITH NEW RHT-B1 ALLIES
WO2012138176A3 (en) D-aptide and retro-inverso aptide with maintained target affinity and improved stability
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
MX2010011055A (en) Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases.